anti-SARS-CoV-2 hyperimmune equine immunoglobulin F(ab')2 fragment (Biological E)

N/A

Report date: 2025/01/26 19:31:50

Base Information

Drug Nameanti-SARS-CoV-2 hyperimmune equine immunoglobulin F(ab')2 fragment (Biological E)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Polyclonal antibodiesBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionImmunoglobulin agonists

TargetsImmunoglobulin

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIndia

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesBiological E Ltd

China Registration ClassN/A

Develop Information

Active CompaniesBiological E Ltd

Inactive CompaniesN/A

Active IndicationsCoronavirus Disease 2019 (COVID-19)

Inactive IndicationsN/A

Other Information

ATC CodeN/A